SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test ...
ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
The market awaits ResMed's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter. It's important for new investors to u ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback